Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-β receptor II and human immunoglobulin Fc for breast cancer therapy

Prem Seth, Zhen Guo Wang, Amanda Pister, M. Behzad Zafar, Sung Kim, Theresa Guise, Lalage Wakefield

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

We have developed an approach to cancer gene therapy in which the oncolytic effects of an adenoviral vector have been combined with selective expression of a soluble form of transforming growth factor (TGF)-β receptor II fused with Fc (sTGFβRIIFc). We chose to use adenoviral dl01/07 mutant because it can replicate in all cancer cells regardless of their genetic defects. An oncolytic adenovirus expressing sTGFβRIIFc (Ad.sT-βRFc) was constructed by homologous recombination. Infection of MDA-MB-231 and MCF-7 human breast cancer cells with Ad.sTβRFc produced sTGFβRIIFc, which was released into the media. The conditioned media containing sTGFβRIIFc could bind with TGF-β1 and inhibited TGF-β-dependent transcription in target cells. Infection of MDA-MB-231, MCF-7, and 76NE human breast cancer cells with Ad.sTβRFc resulted in high levels of viral replication, comparable to that of a wild-type dl309 virus. Although some viral replication was observed in actively dividing normal human lung fibroblasts, there was no replication in nonproliferating normal cells. Direct injection of Ad.sTβRFc into MDA-MB-231 human breast xenograft tumors grown in nude mice resulted in a significant inhibition of tumor growth, causing tumor regression in more than 85% of the animals. These results indicate that it is possible to construct an oncolytic virus expressing sTGFβRIFc in which both viral replication and transgene expression remain intact, and the recombinant adenovirus is oncolytic in a human tumor xenograft model. On the basis of these results we believe that it may be feasible to develop a cancer gene therapy approach using Ad.sTβRFc as an antitumor agent.

Original languageEnglish (US)
Pages (from-to)1152-1160
Number of pages9
JournalHuman Gene Therapy
Volume17
Issue number11
DOIs
StatePublished - Nov 2006
Externally publishedYes

Fingerprint

Immunoglobulin Fc Fragments
Growth Factor Receptors
Transforming Growth Factors
Adenoviridae
Breast Neoplasms
Neoplasm Genes
Heterografts
Genetic Therapy
Neoplasms
Oncolytic Viruses
Therapeutics
Homologous Recombination
Conditioned Culture Medium
Infection
Transgenes
Nude Mice
Antineoplastic Agents
Fibroblasts
Viruses
Lung

ASJC Scopus subject areas

  • Genetics

Cite this

Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-β receptor II and human immunoglobulin Fc for breast cancer therapy. / Seth, Prem; Wang, Zhen Guo; Pister, Amanda; Zafar, M. Behzad; Kim, Sung; Guise, Theresa; Wakefield, Lalage.

In: Human Gene Therapy, Vol. 17, No. 11, 11.2006, p. 1152-1160.

Research output: Contribution to journalArticle

Seth, Prem ; Wang, Zhen Guo ; Pister, Amanda ; Zafar, M. Behzad ; Kim, Sung ; Guise, Theresa ; Wakefield, Lalage. / Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-β receptor II and human immunoglobulin Fc for breast cancer therapy. In: Human Gene Therapy. 2006 ; Vol. 17, No. 11. pp. 1152-1160.
@article{4549905128464df7a549611480600354,
title = "Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-β receptor II and human immunoglobulin Fc for breast cancer therapy",
abstract = "We have developed an approach to cancer gene therapy in which the oncolytic effects of an adenoviral vector have been combined with selective expression of a soluble form of transforming growth factor (TGF)-β receptor II fused with Fc (sTGFβRIIFc). We chose to use adenoviral dl01/07 mutant because it can replicate in all cancer cells regardless of their genetic defects. An oncolytic adenovirus expressing sTGFβRIIFc (Ad.sT-βRFc) was constructed by homologous recombination. Infection of MDA-MB-231 and MCF-7 human breast cancer cells with Ad.sTβRFc produced sTGFβRIIFc, which was released into the media. The conditioned media containing sTGFβRIIFc could bind with TGF-β1 and inhibited TGF-β-dependent transcription in target cells. Infection of MDA-MB-231, MCF-7, and 76NE human breast cancer cells with Ad.sTβRFc resulted in high levels of viral replication, comparable to that of a wild-type dl309 virus. Although some viral replication was observed in actively dividing normal human lung fibroblasts, there was no replication in nonproliferating normal cells. Direct injection of Ad.sTβRFc into MDA-MB-231 human breast xenograft tumors grown in nude mice resulted in a significant inhibition of tumor growth, causing tumor regression in more than 85{\%} of the animals. These results indicate that it is possible to construct an oncolytic virus expressing sTGFβRIFc in which both viral replication and transgene expression remain intact, and the recombinant adenovirus is oncolytic in a human tumor xenograft model. On the basis of these results we believe that it may be feasible to develop a cancer gene therapy approach using Ad.sTβRFc as an antitumor agent.",
author = "Prem Seth and Wang, {Zhen Guo} and Amanda Pister and Zafar, {M. Behzad} and Sung Kim and Theresa Guise and Lalage Wakefield",
year = "2006",
month = "11",
doi = "10.1089/hum.2006.17.1152",
language = "English (US)",
volume = "17",
pages = "1152--1160",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "11",

}

TY - JOUR

T1 - Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-β receptor II and human immunoglobulin Fc for breast cancer therapy

AU - Seth, Prem

AU - Wang, Zhen Guo

AU - Pister, Amanda

AU - Zafar, M. Behzad

AU - Kim, Sung

AU - Guise, Theresa

AU - Wakefield, Lalage

PY - 2006/11

Y1 - 2006/11

N2 - We have developed an approach to cancer gene therapy in which the oncolytic effects of an adenoviral vector have been combined with selective expression of a soluble form of transforming growth factor (TGF)-β receptor II fused with Fc (sTGFβRIIFc). We chose to use adenoviral dl01/07 mutant because it can replicate in all cancer cells regardless of their genetic defects. An oncolytic adenovirus expressing sTGFβRIIFc (Ad.sT-βRFc) was constructed by homologous recombination. Infection of MDA-MB-231 and MCF-7 human breast cancer cells with Ad.sTβRFc produced sTGFβRIIFc, which was released into the media. The conditioned media containing sTGFβRIIFc could bind with TGF-β1 and inhibited TGF-β-dependent transcription in target cells. Infection of MDA-MB-231, MCF-7, and 76NE human breast cancer cells with Ad.sTβRFc resulted in high levels of viral replication, comparable to that of a wild-type dl309 virus. Although some viral replication was observed in actively dividing normal human lung fibroblasts, there was no replication in nonproliferating normal cells. Direct injection of Ad.sTβRFc into MDA-MB-231 human breast xenograft tumors grown in nude mice resulted in a significant inhibition of tumor growth, causing tumor regression in more than 85% of the animals. These results indicate that it is possible to construct an oncolytic virus expressing sTGFβRIFc in which both viral replication and transgene expression remain intact, and the recombinant adenovirus is oncolytic in a human tumor xenograft model. On the basis of these results we believe that it may be feasible to develop a cancer gene therapy approach using Ad.sTβRFc as an antitumor agent.

AB - We have developed an approach to cancer gene therapy in which the oncolytic effects of an adenoviral vector have been combined with selective expression of a soluble form of transforming growth factor (TGF)-β receptor II fused with Fc (sTGFβRIIFc). We chose to use adenoviral dl01/07 mutant because it can replicate in all cancer cells regardless of their genetic defects. An oncolytic adenovirus expressing sTGFβRIIFc (Ad.sT-βRFc) was constructed by homologous recombination. Infection of MDA-MB-231 and MCF-7 human breast cancer cells with Ad.sTβRFc produced sTGFβRIIFc, which was released into the media. The conditioned media containing sTGFβRIIFc could bind with TGF-β1 and inhibited TGF-β-dependent transcription in target cells. Infection of MDA-MB-231, MCF-7, and 76NE human breast cancer cells with Ad.sTβRFc resulted in high levels of viral replication, comparable to that of a wild-type dl309 virus. Although some viral replication was observed in actively dividing normal human lung fibroblasts, there was no replication in nonproliferating normal cells. Direct injection of Ad.sTβRFc into MDA-MB-231 human breast xenograft tumors grown in nude mice resulted in a significant inhibition of tumor growth, causing tumor regression in more than 85% of the animals. These results indicate that it is possible to construct an oncolytic virus expressing sTGFβRIFc in which both viral replication and transgene expression remain intact, and the recombinant adenovirus is oncolytic in a human tumor xenograft model. On the basis of these results we believe that it may be feasible to develop a cancer gene therapy approach using Ad.sTβRFc as an antitumor agent.

UR - http://www.scopus.com/inward/record.url?scp=33750979574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750979574&partnerID=8YFLogxK

U2 - 10.1089/hum.2006.17.1152

DO - 10.1089/hum.2006.17.1152

M3 - Article

C2 - 17032151

AN - SCOPUS:33750979574

VL - 17

SP - 1152

EP - 1160

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 11

ER -